5.4 Hormonal Contraceptive, Naloxone & Post-Exposure Prophylaxis (PEP/PrEP) Prescribing
Key Takeaways
- Pharmacist standing orders and statewide protocols permit direct prescribing of naloxone, self-administered hormonal contraceptives, and HIV PrEP/PEP without a patient-specific prescription.
- Naloxone standing orders cover intranasal 4 mg spray and auto-injectors, with mandatory patient education on overdose recognition, rescue breathing, 911 activation, and Good Samaritan liability immunity.
- Hormonal contraceptive prescribing requires a standardized self-screening questionnaire, blood pressure measurement, and screening for CDC US MEC Category 4 contraindications such as BP ≥160/100 mmHg or migraine with aura.
- HIV Pre-Exposure Prophylaxis (PrEP) protocol prescribing mandates documented negative HIV testing within 7–14 days prior, baseline eGFR/renal panel, and a maximum 60 to 90-day supply before PCP referral.
- HIV Post-Exposure Prophylaxis (PEP) protocols authorize immediate emergency 28-day antiretroviral therapy initiation within 72 hours of exposure, with written notification sent to the primary care physician.
5.4 Hormonal Contraceptive, Naloxone & Post-Exposure Prophylaxis (PEP/PrEP) Prescribing
MPJE Core Concept: State legislative frameworks authorize pharmacists to independently or protocol-prescribe critical public health medications via statewide protocols or standing orders. Key prescribing domain areas include opioid overdose reversal (naloxone), self-administered hormonal contraceptives, and HIV Pre-Exposure (PrEP) and Post-Exposure (PEP) Prophylaxis. Pharmacists must strictly evaluate clinical contraindications, perform mandatory patient screening, order baseline laboratory tests, and adhere to physician notification rules.
1. Legal Models of Pharmacist Prescribing Authority
Pharmacist prescribing operates under four distinct statutory models across state jurisdictions:
- Statewide Protocols: Promulgated by the Board of Pharmacy in consultation with the State Medical Board, authorizing any qualified pharmacist in the state to prescribe specific drug classes upon completing designated training.
- Standing Orders: A statewide or regional medical order issued by a state health officer (e.g., Director of the Department of Public Health) permitting pharmacists to dispense specific medications (e.g., naloxone) without an individual prescription.
- Collaborative Practice Agreements (CPAs): Site-specific or practice-specific agreements negotiated between individual prescribers and pharmacists.
- Autonomous / Independent Prescribing Authority: Granted in select states for specific categories of medications based on pharmacist clinical judgment and standardized screening.
2. Naloxone Prescribing & Harm Reduction Protocols
Naloxone standing orders and statewide protocols empower pharmacists to distribute opioid antagonists directly to patients, family members, or community bystanders.
Prescribing & Formulations
- Formulations: Intranasal spray (4 mg/0.1 mL single-dose nasal spray), intramuscular/subcutaneous autoinjectors, and injectable naloxone vials.
- Target Candidate Identification:
- Patients receiving high-dose opioid therapy (≥50 Morphine Milligram Equivalents [MME] per day).
- Patients concurrently prescribed opioids and benzodiazepines or other CNS depressants.
- Patients with a history of substance use disorder, prior opioid overdose, or loss of opioid tolerance (e.g., recent release from incarceration or detoxification).
- Family members, friends, or community members in a position to assist individuals at risk of overdose.
Mandatory Patient Education & Immunity Protections
- Counseling Requirements: Pharmacists must educate recipients on recognizing signs of opioid overdose (unresponsiveness, respiratory depression, pinpoint pupils, cyanosis), call 911 immediately, administer naloxone, perform rescue breathing/CPR, and stay with the patient until emergency responders arrive.
- Good Samaritan & Civil Immunity: State laws provide civil and criminal liability immunity for pharmacists prescribing/dispensing naloxone in good faith under standing orders, as well as laypersons administering naloxone during an overdose emergency.
3. Hormonal Contraceptive Prescribing Protocols
Statewide contraceptive protocols permit pharmacists to evaluate patients and prescribe self-administered hormonal contraceptives, including Combined Oral Contraceptive pills (COCs), Progestin-Only Pills (POPs), transdermal contraceptive patches, vaginal contraceptive rings, and depot medroxyprogesterone acetate (DMPA) injections.
Clinical Screening & Assessment Protocol
| Assessment Step | Clinical Requirement & Operational Rule |
|---|---|
| Self-Screening Questionnaire | Patient must complete a standardized self-screening risk assessment form covering medical history, current medications, and contraindications. |
| Blood Pressure Measurement | Mandatory in-clinic blood pressure measurement required prior to prescribing estrogen-containing products (COCs, patch, ring). |
| CDC US MEC Screening | Pharmacist must screen for CDC US Medical Eligibility Criteria Category 4 (unacceptable health risk / absolute contraindications). |
| PCP Notification & Referral | Written notification sent to patient's primary care physician within state timeframe (e.g., 14 days); mandatory referral to PCP for routine gynecological care. |
CDC US MEC Category 4 Absolute Contraindications for Estrogen-Containing Contraceptives
| Medical Condition | Clinical Risk / Complication | Prescribing Action |
|---|---|---|
| Uncontrolled Hypertension | Systolic BP ≥160 mmHg or Diastolic BP ≥100 mmHg | Do NOT prescribe combined estrogen therapy. Refer or select Progestin-Only Pill (POP). |
| Thromboembolic History | Active or past history of DVT, Pulmonary Embolism, or known thrombogenic mutations | Absolute Contraindication. Combined estrogen therapy strictly prohibited. |
| Age ≥35 and Smoker | Age ≥35 years AND currently smoking ≥15 cigarettes per day | Absolute Contraindication. High risk of stroke and MI; select POP or non-hormonal. |
| Migraine with Aura | Migraine headaches with focal neurological aura at any age | Absolute Contraindication. Significant stroke risk; select POP or non-hormonal. |
| Breast Cancer | Active or past history of breast cancer | Absolute Contraindication for both estrogen and progestin therapy. |
| Severe Liver Disease | Acute viral hepatitis, severe cirrhosis, or hepatocellular adenoma/tumor | Absolute Contraindication. Impaired steroid hormone metabolism. |
4. HIV Pre-Exposure (PrEP) & Post-Exposure (PEP) Prescribing
Statewide protocols increasingly grant pharmacists authority to initiate HIV PrEP and PEP to expand access to HIV prevention.
HIV Pre-Exposure Prophylaxis (PrEP) Protocol Rules
- Approved Regimens: Daily oral Emtricitabine/Tenofovir Disoproxil Fumarate (TDF/FTC - Truvada) or Emtricitabine/Tenofovir Alafenamide (TAF/FTC - Descovy).
- Mandatory Baseline Screening:
- Negative HIV Test: Documented negative HIV-1 antigen/antibody test performed within 7 to 14 days prior to initiation.
- Renal Function: Baseline estimated Glomerular Filtration Rate (eGFR ≥60 mL/min for TDF/FTC; eGFR ≥30 mL/min for TAF/FTC).
- Hepatitis B & STI Screening: Baseline Hepatitis B virus (HBV) surface antigen testing and STI screening.
- Prescribing Limit: Pharmacists may prescribe up to a 60 to 90-day supply of PrEP. Patients must be referred to a primary care provider or specialist for ongoing monitoring and refill management beyond the initial protocol window.
HIV Post-Exposure Prophylaxis (PEP) Emergency Protocol Rules
- Indication: Emergency prophylaxis following potential non-occupational or occupational HIV exposure (e.g., unprotected intercourse, needle sharing, needle stick).
- Critical Window: Must be initiated as soon as possible, ideally within 2 hours and strictly within 72 hours of exposure. Protocols started after 72 hours are ineffective.
- Regimen Duration: A complete 28-day continuous course of 3-drug antiretroviral therapy (e.g., TDF/FTC plus Raltegravir or Dolutegravir).
- Required Procedures: Immediate rapid HIV testing prior to initiation; baseline renal and hepatic labs; mandatory referral to a primary care or infectious disease specialist within 72 hours for ongoing follow-up.
A 38-year-old female patient who smokes 20 cigarettes per day requests a prescription for combined oral contraceptive pills at a pharmacy operating under a statewide contraceptive protocol. Her blood pressure reading in the clinic is 128/82 mmHg. How should the pharmacist proceed?
Under statewide naloxone standing orders, which clinical patient scenario represents a primary indication for co-prescribing or dispensing intranasal naloxone?
A patient presents to the pharmacy 36 hours after potential non-occupational exposure to HIV requesting Post-Exposure Prophylaxis (PEP) under a statewide protocol. What is the correct protocol requirement regarding timing and treatment duration?
Prior to initiating a pharmacist-prescribed 60-day supply of HIV Pre-Exposure Prophylaxis (PrEP) under a statewide protocol, which laboratory requirement must be documented?